Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15091968 | 1.00 | EPHX2 (0.47) | EPHX2CTSBCTSSCTSKPTPN1 | |
| SCHEMBL22384157 | 0.88 | EPHX2 (0.44) | EPHX2CTSBCTSSCTSKPTPN1 | |
| SCHEMBL15037131 | 0.88 | EPHX2 (0.44) | EPHX2CTSBCTSSCTSKPTPN1 | |
| SCHEMBL22449277 | 0.88 | MME (0.49) | CTSBCTSSCTSKPTPN1GPR132 | |
| SCHEMBL15037189 | 0.88 | MME (0.49) | CTSBCTSSCTSKPTPN1GPR132 | |
| SCHEMBL15019743 | 0.87 | EPHX2 (0.62) | EPHX2CTSBCTSSCTSKPTPN1 | |
| SCHEMBL22448948 | 0.86 | MME (0.53) | CTSBCTSSCTSKPTPN1GPR132 | |
| SCHEMBL15018822 | 0.86 | PTPN1 (0.47) | CTSBCTSSCTSKPTPN1GPR132 | |
| SCHEMBL15018825 | 0.86 | PTPN1 (0.47) | CTSBCTSSCTSKPTPN1GPR132 | |
| SCHEMBL22449043 | 0.86 | MME (0.53) | CTSBCTSSCTSKPTPN1GPR132 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008056-B1 | NOVEL GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-12-09 | — | — | EP | disclosed |
| EP-2791112-B1 | CARBOXYLIC ACID DERIVATIVES COMPRISING FOUR CYCLES ACTING AS GLP-1 RECEPTOR MODULATORS FOR THERAPY OF DISEASES SUCH AS DIABETES | CELGENE INT II SÀRL (CH) | 2020-09-23 | — | — | EP | disclosed |
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10259823-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-04-16 | — | — | US | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-11-02 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-9598430-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-03-21 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160214993-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-07-28 | — | — | US | disclosed |
| US-9260427-B2 | GLP-1 receptor modulators | RECEPTOS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9187522-B2 | GLP-1 receptor modulators | RECEPTOS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150038416-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2015-02-05 | — | — | US | disclosed |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2015-01-08 | — | — | US | disclosed |
| US-8778923-B2 | GLP-1 receptor modulators | RECEPTOS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130178420-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | EPHX2 4296/4885CTSB 1692/4885CTSS 3233/4885 |
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | EPHX2 4296/4885CTSB 1692/4885CTSS 3233/4885 |
| US-20160214993-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | EPHX2 4296/4885CTSB 1692/4885CTSS 3233/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | EPHX2 4296/4885CTSB 1692/4885CTSS 3233/4885 |
| US-20130178420-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | EPHX2 4053/4885CTSB 1572/4885CTSS 2806/4885 |
| US-20150038416-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | EPHX2 4053/4885CTSB 1572/4885CTSS 2806/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | EPHX2 4326/4885CTSB 1992/4885CTSS 3308/4885 |
| US-10259823-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | EPHX2 4326/4885CTSB 1992/4885CTSS 3308/4885 |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | EPHX2 4296/4885CTSB 1692/4885CTSS 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.